Christina Addison is a laboratory research scientist at the Ottawa Hospital Research Institute, and an Associate Professor at the University of Ottawa. She works closely with surgeons and oncologists and has a long-standing interest in clinical correlative analyses. The laboratory is also focused on analysis and identification of circulating or tissue-derived predictive biomarkers associated with cancer outcomes. A major current focus in the lab is regarding evaluation of miRNA and its ability to be used to identify patients at higher risk of tumor recurrence or metastasis, or treatment response.
*Howe, G., Xiao, B., Zhao, H., Al-Zahrani, K., Hasim, M.S., Villeneuve, J., Goss, G.D., Sekhon, H., Sabourin, L., Dimitroulakos, J., Addison, C.L. Enhanced anti-tumor activity of erlotinib in combination with focal adhesion kinase inhibitors in non-small cell lung cancer. In revision at PLoS One.
Addison, C.L., Ding, K., Seymour, L., Zhao, H., Laurie, S., Shepherd, F.A., Goss, G.D., Bradbury, P.A. 2015. Analysis of serum protein levels of angiogenic factors and their soluble receptors as markers of response to cediranib in the NCIC CTG BR.24 clinical trial. Lung Cancer, Nov; 90(2):288-95.
Addison, C.L., Pond, G.R, Cochrane, B., Zhao, H., Chia, S, Levine, M.N., Clemons, M. 2015. Correlation of Baseline K., Biomarkers with Clinical Outcomes and Response to Fulvestrant with Vandetanib or Placebo in Patients with Bone Predominant Metastatic Breast Cancer. An OCOG ZAMBONEY Sub-study. Journal of Bone Oncology. 4(2):47-53.
Addison, C.L., Bouganim, N., Kuchuk, I., Hilton, J., Vandermeer, L., Dent, S., Amir, E., Hopkins, S., Segal, R., Song, X., Gertler, S., Mazzarello, S., Dranitsaris, G., Ooi, D., Clemons, M. 2014. A Phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal related events. Breast Cancer Research and Treatment, Apr;144(3):615-24. doi: 10.1007/s10549-014-2906-x. Epub 2014 Mar 18.
*Honeywell, D.R., Cabrita, M.A., Zhao, H., Dimitroulakos, J., Addison, C.L. 2013. miR-105 Inhibits Prostate Tumor Growth by Suppressing CDK6 Levels. PLoS One, 8(8):e70515.doi:10.1371/journal.pone.0070515.
Al-Baimani K, Bazzarelli A, Clemons M, Robertson SJ, Addison C, Arnaout A. 2015. Invasive Pleomorphic Lobular Carcinoma of the Breast: Pathologic, Clinical, and Therapeutic Considerations. Clin Breast Cancer. pii: S1526-8209(15)00144-5. doi: 10.1016/j.clbc.2015.06.010.
Jacobs C, Ibrahim MF, Clemons M, Hutton B, Simos D, Caudrelier JM, Graham ID, Smith S, Addison C, Arnaout A. 2015. Treatment choices for patients with invasive lobular breast cancer: a doctor survey. J Eval Clin Pract., 21(4):740-8. doi: 10.1111/jep.12379.
Arnaout A, Robertson S, Kuchuk I, Simos D, Pond GR, Addison CL, Namazi M, Clemons M. 2015. Evaluating the feasibility of performing window of opportunity trials in breast cancer. Int J Surg Oncol. 2015:785793.
Addison CL, Pond GR, Zhao H, Mazzarello S, Vandermeer L, Goldstein R, Amir E, Clemons M. 2014. Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases. Springerplus. 2014 Oct 1;3:577. doi: 10.1186/2193-1801-3-577.
Addison, C.L., Bouganim, N., Kuchuk, I., Hilton, J., Vandermeer, L., Dent, S., Amir, E., Hopkins, S., Segal, R., Song, X., Gertler, S., Mazzarello, S., Dranitsaris, G., Ooi, D., Clemons, M. 2014. A Phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal related events. Breast Cancer Research and Treatment, Apr;144(3):615-24. doi: 10.1007/s10549-014-2906-x. Epub 2014 Mar 18.
